Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis

Immunological differences between males and females in response to viral vaccines are well known. This the first review examine them for Human Papilloma Virus. We conducted a systematic meta-analysis of immunogenicity Quadrivalent Virus Vaccine qHPVV. searched Medline, Embase, CENTRAL trials published until September 17, 2019. Inclusion criteria were 3-doses reporting geometric mean titers (GMTs). performed random-effects meta-analyses meta-regression separated by age group sex. Our search yielded 1809 unique studies. 334 full texts screened data from 18 studies extracted. Females had higher pooled than all groups. Log transformed GMTs male children (<16) years were: against HPV6: 6·62 (95% CI 6·29–6·94; I2 = 86·0%), HPV11: 7·07 6·90–7·23; 63.1%), HPV16: 8·53 8·28–8·78; 73·0%), HPV18 7·21 7·08–7·34; 26·4%). In females: HPV6 7·10 6·79–7·41; 96·6%), 7·32 7·15–7·50; 90·6%), 8·71 8·52–8·91; 90·2%), 7·35 7·11–7·58; 92·7%). meta-regression, sexual difference was significant (p 0·022) with similar tendency HPV11 0·066) 0·079). Immunogenicity significantly adults < 0·001). have antibody HPV after receiving qHPVV do males. The is bigger low-risk strains. Adjusting doses schedules each sex should be explored further.